Ranibizumab is a monoclonal antibody
fragment created from the same parent mouse antibody as bevacizumab. It is an
anti-angiogenic that has been approved to treat the “wet” type of age-related
macular degeneration, a common form of age-related vision loss.
Its effectiveness is similar to that of bevacizumab. Its rates of side effects
also appear similar. However, ranibizumab typically costs $2,000 a
dose, while the equivalent dose of bevacizumab typically costs $50.
Ranibizumab was developed by Genentech and is marketed in the United States by
Genentech and elsewhere by Novartis, under the brand name Lucentis.
Pharmacology Ranibizumab is a monoclonal antibody
that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A, a
mechanism similar to Bevacizumab. Medical uses
It is often used for age-related wet macular degeneration. Its effectiveness
is similar to that of bevacizumab. Side effects
A 2014 Cochrane review did not find a difference between bevacizumab and
ranibizumab in deaths or total severe side effects when used for macular
degeneration. There; however, was not a lot of evidence and thus this conclusion
is not that certain. Ranibizumab does appears to result in a
lower risk of stomach and intestinal problems. It is also associated with a
low rate of eye related side effects. The most common side effects in clinical
trials were conjunctival haemorrhage, eye pain, vitreous floaters, increased
intraocular pressure, and intraocular inflammation.
Although there is a theoretical risk for arterial thromboembolic events in
patients receiving VEGF-inhibitors by intravitreal injection, the observed
incidence rate was low (